QIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product GroupsBusiness Wire • 02/07/23
Qiagen (QGEN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 01/31/23
QIAGEN Launches EZ2 Connect MDx Platform for Automated Sample Processing in Diagnostic LabsBusiness Wire • 01/17/23
QIAGEN N.V. to Release Results for Q4 and Full-Year Results 2022 and Hold WebcastBusiness Wire • 01/17/23
QIAGEN Completes Acquisition of Verogen, Strengthening Leadership in Human ID / Forensics With NGS TechnologiesBusiness Wire • 01/09/23
QIAGEN and Helix Launch Exclusive Partnership to Advance Next-Generation Sequencing Companion Diagnostics in Hereditary DiseasesBusiness Wire • 01/05/23
Helix and QIAGEN Form Exclusive Global Partnership to Develop and Commercialize Companion Diagnostics for Hereditary DiseasesPRNewsWire • 01/05/23
QIAGEN receives FDA approval for companion diagnostic to Mirati Therapeutics' KRAZATI in non-small cell lung cancerBusiness Wire • 12/13/22
QIAGEN launches monkeypox test for NeuMoDx platform to fight global outbreak by boosting research and surveillanceBusiness Wire • 11/21/22
QIAGEN Exceeds Outlook for Q3 2022 with 18% CER Sales Growth in Non-COVID Product Portfolio and Raises Full-Year 2022 OutlookBusiness Wire • 11/07/22